Article
Chemistry, Medicinal
Chun-Feng Huang, Ming-Shi Shiao, Tso-Yen Mao
Summary: This study demonstrates for the first time that zoledronic acid monotherapy not only benefits bone mass but also muscle mass in osteoporosis patients.
DRUG DESIGN DEVELOPMENT AND THERAPY
(2021)
Article
Engineering, Biomedical
Fei Jia, Lifo Ruan, Chuanchao Du, Yu Liu, Xiaomeng Cai, Rui Dou, Jiayu Zhang, Xiaoguang Liu, Jun Chen, Xingcai Zhang, Zhifang Chai, Yi Hu
Summary: An OCs' microenvironment-responsive nanoplatform has been developed, which can effectively inhibit the activity of mature OCs, reverse systemic bone mass loss, and reduce the adverse effects of zoledronic acid.
Article
Medicine, General & Internal
Nazar M. Kostyshyn, Siemowit Muszynski, Ewa Tomaszewska, Agnieszka Tomczyk-Warunek, Iwona Puzio, Piotr Dobrowolski
Summary: The study compared the effectiveness of zoledronic acid and whole-body vibration as treatment methods for early obesity/immobility-related osteoporosis in male rat models. The results showed that short-term whole-body vibration therapy (up to 8 weeks) can improve bone remodeling in rat models with obesity and limited mobility.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Medicine, General & Internal
Taewook Kang, Si Young Park, Soon Hyuck Lee, Jong Hoon Park, Seung Woo Suh
Summary: This study compared the effects of DEN and ZOL on postmenopausal women with osteoporosis and found that DEN was associated with greater increase in BMD and TBS, as well as greater inhibition of bone remodeling compared with ZOL.
JOURNAL OF KOREAN MEDICAL SCIENCE
(2022)
Article
Dentistry, Oral Surgery & Medicine
Marcelo Vitale, Monica Grazieli Correa, Edilson Ervolino, Fabiano Ribeiro Cirano, Fernanda Vieira Ribeiro, Mabelle Freitas Monteiro, Marcio Zaffalon Casati, Suzana Peres Pimentel
Summary: This study evaluated the effect of resveratrol (RES) on the prevention of medication-related osteonecrosis of the jaws (MRONJ) in ovariectomized (OVX) rats treated with zoledronate (ZOL). The results showed that RES reduced tissue impairment caused by ZOL, but it could not prevent the occurrence of MRONJ.
Article
Biochemistry & Molecular Biology
Wei Lin, Xing-fu Li, Dong-cheng Ren, Meng Song, Li Duan, Jin-zhu Liu, Zi-rui Zhan
Summary: The study demonstrated that ZOL treatment suppressed RANKL expression through the miR-101-3p/RANKL, miR-302/PRKACB/RANKL, and miR-145/SMAD3/RANKL signaling pathways. Down-regulation of RANKL by ZOL treatment alleviated osteoporosis in HIV-positive subjects on tenofovir therapy.
MOLECULAR MEDICINE
(2021)
Article
Endocrinology & Metabolism
Moritz Weigl, Roland Kocijan, James Ferguson, Gabriele Leinfellner, Patrick Heimel, Xaver Feichtinger, Peter Pietschmann, Johannes Grillari, Jochen Zwerina, Heinz Redl, Matthias Hackl
Summary: MicroRNAs play a regulatory role in bone homeostasis, and circulating microRNAs are considered as potential biomarkers for bone health. This study investigated the impact of anti-osteoporotic treatments on circulating microRNAs in OVX and SHAM rats, revealing that these treatments can reverse bone loss and modulate specific miRNA expressions. The findings suggest that bone-related miRNAs could serve as promising biomarkers for monitoring treatment efficacy in osteoporosis.
JOURNAL OF BONE AND MINERAL RESEARCH
(2021)
Article
Medicine, General & Internal
Masashi Uehara, Yukio Nakamura, Takako Suzuki, Masaki Nakano, Jun Takahashi
Summary: This study compared the efficacy and safety of ibandronate and zoledronic acid in Japanese postmenopausal osteoporotic patients, finding that both drugs significantly and safely improved bone turnover markers and BMD during 30 months of treatment. The ZOL group tended to exhibit greater gains in BMD compared to the IBN group, warranting further investigation.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Endocrinology & Metabolism
Kristin M. D'Silva, Sara Jane Cromer, Elaine W. Yu, Michael Fischer, Seoyoung C. Kim
Summary: This study found that compared to denosumab, treatment with zoledronic acid for osteoporosis and possibly malignancy-related bone disease is associated with a modestly increased risk of incident atrial fibrillation in the first year of treatment.
JOURNAL OF BONE AND MINERAL RESEARCH
(2021)
Review
Pharmacology & Pharmacy
Biao Wang, Yi Zhan, Liang Yan, Dingjun Hao
Summary: The article discusses the role of zoledronic acid in improving osteoporosis, including its inhibition of osteoclast differentiation and induction of osteoclast apoptosis. Zoledronic acid is an effective anti-osteoporotic drug that increases bone density and reduces bone resorption by acting on osteoclasts.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Orthopedics
Earl Bogoch, Francesc A. Marcano-Fernandez, Emil H. Schemitsch, Qi Zhou, Sofia Bzovsky, Mohit Bhandari, Prism S. Schneider, Marc Swiontkowski, Sheila Sprague
Summary: Subsequent fractures, including second hip fractures, occur frequently and early following an index femoral neck fracture in elderly patients. However, interventions to prevent subsequent fractures are not sufficiently implemented in high-risk patients, highlighting the care gap in fragility fracture management.
JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME
(2022)
Article
Medicine, General & Internal
Wei Luo, Jin Zhang, Ling Xu, Yao Zhou, Dan Xu, Qiuju Lv, Yi Xiao, Qin Yang
Summary: This cohort study found that zoledronic acid (ZA) may have a protective effect on lipid metabolism in postmenopausal women with osteoporosis. In postmenopausal women with lipid disorders suffering from osteoporosis, treatment with ZA combined with atorvastatin significantly reduced blood lipid levels compared to atorvastatin alone.
POSTGRADUATE MEDICINE
(2022)
Article
Chemistry, Multidisciplinary
Marwa Y. Shaheen, Amani M. Basudan, Abdurahman A. Niazy, Jeroen J. J. P. van den Beucken, John A. Jansen, Hamdan S. Alghamdi
Summary: The study demonstrates that systemic intravenous administration of zoledronate either before or after surgery improves the regeneration of bone defects grafted with inorganic cancellous bovine bone particles in osteoporotic conditions. However, continued pre- and post-surgical zoledronate treatment did not show a favorable effect on bone repair.
APPLIED SCIENCES-BASEL
(2021)
Article
Oncology
Christopher Li, Meghan R. Flanagan, Mei-Tzu C. Tang, Peggy L. Porter, Kathleen E. Malone
Summary: This study demonstrates that bisphosphonate use is associated with a lower risk of subsequent invasive breast cancer among women with a history of DCIS, suggesting a potential preventative approach for this high-risk population.
Review
Multidisciplinary Sciences
Christopher Jackson, Alexandra L. J. Freeman, Zsofia Szlamka, David J. Spiegelhalter
Summary: This meta-analysis identified and quantified a range of potential adverse effects associated with bisphosphonate drugs in breast cancer patients, most of which are clinically recognized. The study showed that bisphosphonate drugs may lead to various adverse effects, but there was little variation in side effects between patients of different ages, menopausal status, cancer types, and concurrent breast cancer therapies.